Smith v. American Home Prod. Corp.

855 A.2d 608, 372 N.J. Super. 105
CourtNew Jersey Superior Court Appellate Division
DecidedSeptember 23, 2003
StatusPublished
Cited by22 cases

This text of 855 A.2d 608 (Smith v. American Home Prod. Corp.) is published on Counsel Stack Legal Research, covering New Jersey Superior Court Appellate Division primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Smith v. American Home Prod. Corp., 855 A.2d 608, 372 N.J. Super. 105 (N.J. Ct. App. 2003).

Opinion

855 A.2d 608 (2003)
372 N.J.Super. 105

Theresa SMITH Plaintiff,
v.
AMERICAN HOME PRODUCTS CORP. WYETH-AYERST PHARMACEUTICAL, et al., Defendants.

Superior Court of New Jersey, Law Division, Middlesex County.

Argued August 8, 2003.
Decided September 23, 2003.

*610 Ellen Relkin (Weitz & Luxenberg), New York City and Kevin Haverty (Williams, Cuker & Berezofsky, Philadelphia, PA), for plaintiff.

Anita Hotchkiss (Porzio, Bromberg & Newman), Morristown and Kevin Gardner (Connell Foley), Roseland, for defendants.

Anne Patterson (Riker, Danzig, Scherer, Hyland & Perretti), Morristown, for amicus curiae New Jersey Defense Association.

Diane Sullivan (Dechert), Princeton, for amicus curiae Defense Research Institute.

Mark Lesser (Kronisch & Lesser), Livingston, for amicus curiae Association of Trial Lawyers of America.

CORODEMUS, J.S.C.

Presently before this court is a unified motion by defendants, the phenylpropanolamine ("PPA") manufacturers, compelling ex parte physician interviews and seeking judicial approval of a revised medical authorization. Plaintiffs, consumers of PPA, allege injuries caused from the use of the drug claiming that regulations promulgated pursuant to the Health Insurance Portability and Accountability Act of 1996, Pub.L. 104-191, effective April 14, 2003, ("HIPAA") preempt the informal discovery procedures as permitted under Stempler v. Speidell, 100 N.J. 368, 495 A.2d 857 (1985). Plaintiffs contend that defendants' proposed medical authorization is moot as the standards under Stempler are less stringent than the federal act requiring patients' "protected health information" ("PHI"). 45 C.F.R. § 164.501. The issue of HIPAA's preemption of Stempler is one of first impression in New Jersey.

For the reasons set forth below, the court holds that HIPAA is an express but selective preemption of New Jersey law. *611 It does not conflict with the general principles of N.J.S.A. 2A:84A-22.4[1] and the informal discovery techniques permitted under Stempler. However, the current proposed medical authorization offered by the defense does not comport with HIPAA or the Stempler safeguards. Therefore, the motion is granted in part, denied in part.

I. BACKGROUND

A. HIPAA and the Privacy Rule.

In 1996, the United States Congress enacted the HIPAA, 42 U.S.C.A. § 1320(d) et seq. (HIPAA or "the Act"). One of the primary purposes of the Act is to standardize and increase the efficiency of common electronic transactions in health care through the "administrative simplification"[2] provisions of HIPAA as well as to protect the security and privacy of individually identifiable health information ("IIHI").[3] Congress entrusted the Secretary of the Department of Health and Human Services with the task of creating national standards to "ensure the integrity and confidentiality of the information" to be collected and disseminated. 42 U.S.C.A. § 1320d-2(d)(2)(A). The regulations promulgating these standards as created by the Department of Health and Human Services became effective on April 14, 2003, and are collectively known as "the Privacy Rule," which sets forth standards and procedures for the collection and disclosure of "protected health information" ("PHI").[4] The Privacy Rule establishes patients' rights and requires that health professionals implement various procedures regarding the use of and access to health care information. It prohibits *612 "covered entities" from using and disclosing PHI except as required or permitted by the regulations. 45 C.F.R. § 164.501 and 45 C.F.R. § 160.103. There are three categories of "covered entities": (1) health plans; (2) health care clearing-houses; and (3) health care providers. 45 C.F.R. § 160.103.[5]

The Privacy Rule prohibits covered entities from using or disclosing PHI in any form oral, written or electronic, except as permitted under the Privacy Rule. 45 C.F.R. § 164.502(a). "Use" and "disclosure" are defined very broadly. 45 C.F.R. § 164.501. "Use" includes an examination of PHI; "disclosure" includes divulging or providing access to PHI. The Privacy Rule is also centered on the concept that, when using PHI or when requesting PHI from another covered entity, a covered entity must make reasonable efforts to limit PHI to the "minimum necessary" to accomplish the intended purpose of the use, disclosure or request. 45 C.F.R. § 164.508. In other words, even if a use or disclosure of PHI is permitted, covered entities must make reasonable efforts to disclose only the minimum necessary to achieve the purpose for which it is being used or disclosed. The "minimum necessary" standard was implemented to prevent improper disclosure of PHI, yet to be flexible where a patient waives his or her privacy privilege for confidential medical information.

B. The New Jersey Supreme Court Permits Defense Counsel to Conduct Ex Parte Interviews with Plaintiff's Treating Physicians.

By virtue of filing a suit for personal injury, the plaintiff has placed his or her medical condition in issue, and consequently, has waived some of his or her privacy privilege. Stempler v. Speidell, supra, 100 N.J. at 373, 495 A.2d at 859 (1985) (citing N.J.S.A. 2A:84A-22.1 to -22.7). In Stempler, the Court found that the costs incurred and the time expended during trial preparation justified "personal interviews" as an "informal method of assembling facts and documents in preparation for trial." Id. at 382, 495 A.2d at 864. Defendants often conduct personal interviews of the treating physician of a plaintiff that has filed a suit for personal injury. These informal, personal interviews generally take place outside the presence of plaintiff's counsel. The New Jersey Supreme Court permits defendants to conduct these ex parte interviews of a plaintiff's health care provider so long as the defendant complies with specific patient authorization requirements. Id. at 373-82, 495 A.2d at 859-64. Those requirements are that defense counsel must: "provide plaintiff's counsel with reasonable notice of the time and place of the proposed interview; provide the physician with a description of the anticipated scope of the interview; and communicate with `unmistakable clarity' the fact that the physician's participation in an ex parte interview is voluntary." Id. at 382, 495 A.2d at 864.

II. CONTENTIONS OF THE PARTIES

A. Defendants Argue that Stempler Interviews are Permissible Under HIPAA.

1. Stempler interviews are consistent with HIPAA.

Defendants' briefs and reply assert that there is no conflict between Stempler and HIPAA. They base this declaration on the fact that once a plaintiff has waived his patient-physician privilege, there is no conflict *613 between Stempler and HIPAA. Therefore, according to defendants, this court's preemption analysis is not warranted. HIPAA's broad statutory purpose, according to the defendants, is in harmony with Stempler. The primary purpose of HIPAA, as reflected in its legislative history, is aimed at regulating the commercial behavior of the national health care industry. 68 Fed.Reg. 8334 (Feb. 20, 2003).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Deisy Granados v. Pan American Life Insurance Co.
New Jersey Superior Court App Division, 2026
Lori Lynn Martinolich, Etc. v. New Jersey State Police
New Jersey Superior Court App Division, 2025
W. Va. Dept. of Health and Human Resources/Behavioral Health v. E.H.
778 S.E.2d 728 (West Virginia Supreme Court, 2015)
Caldwell v. Chauvin
464 S.W.3d 139 (Kentucky Supreme Court, 2015)
R.K. v. St. Mary's Medical Center, Inc.
735 S.E.2d 715 (West Virginia Supreme Court, 2012)
Holman v. RASAK
785 N.W.2d 98 (Michigan Supreme Court, 2010)
Holmes v. Nightingale
2007 OK 15 (Supreme Court of Oklahoma, 2007)
Kish v. Graham
40 A.D.3d 118 (Appellate Division of the Supreme Court of New York, 2007)
Herman v. Kratche, Unpublished Decision (11-9-2006)
2006 Ohio 5938 (Ohio Court of Appeals, 2006)
Northlake Medical Center, LLC v. Queen
634 S.E.2d 486 (Court of Appeals of Georgia, 2006)
Michelson v. Wyatt
880 A.2d 458 (New Jersey Superior Court App Division, 2005)
Brigman v. Wyeth, Inc.
895 A.2d 493 (New Jersey Superior Court App Division, 2005)
In Re Diet Drug Litigation
895 A.2d 493 (New Jersey Superior Court App Division, 2005)
Browne v. Horbar
6 Misc. 3d 780 (New York Supreme Court, 2004)
Keshecki v. St. Vincent's Medical Center
5 Misc. 3d 539 (New York Supreme Court, 2004)

Cite This Page — Counsel Stack

Bluebook (online)
855 A.2d 608, 372 N.J. Super. 105, Counsel Stack Legal Research, https://law.counselstack.com/opinion/smith-v-american-home-prod-corp-njsuperctappdiv-2003.